Highlights Inhibrx, Inc.

Equities

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-25 EDT			5-day change	1st Jan Change
15.09 ^USD	-2.46%		+3.57%	-60.29%

06-04	Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing	MT
05-31	Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index	CI

Sanofi Closes Purchase of US Biotech Company Inhibrx	05-30	MT
Sanofi: acquisition of Inhibrx finalized	05-30	CF
Aventis Inc. completed the acquisition of Inhibrx, Inc. from a group of shareholders.	05-29	CI
Inhibrx, Inc. completed the Spin-Off of 92% stake in Inhibrx Biosciences, Inc..	05-28	CI
Inhibrx Shareholders Approve Sale of INBRX-101 Assets to Sanofi	05-24	MT
Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Inhibrx Shares Fall After Q4 Net Loss Widens	02-28	MT
Earnings Flash (INBX) INHIBRX Reports Q4 Revenue $1.6M	02-28	MT
Inhibrx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
Inhibrx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Arecor Therapeutics hails Arestat as 2023 performance "strong"	02-01	AN
Health Care Flat After J&J Earnings -- Health Care Roundup	01-23	DJ
Arecor pleased as investee Inhibrx sells therapy to Sanofi	01-23	AN
Sanofi Agrees to Buy Inhibrx' Rare Disease Candidate For Up To $2.2 Billion	01-23	MT
CAC40: falls back below 7,400, Wall-Street reopens unchanged	01-23	CF
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday as Investors Await Earnings Peak	01-23	MT
Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- Update	01-23	DJ
Sanofi to Acquire Inhibrx for Up to $2.2 Billion	01-23	MT
CAC40: little movement, caution prevails	01-23	CF
Sanofi: agreement to acquire Inhibrx	01-23	CF

No results for this search